Clinical Trial Update: Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of zoledronic acid and BMS-275291 for prostate cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• BMS-275291
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED